ITGAX and systemic lupus erythematosus: One notable difference in terms of checkpoint inhibitor expression was the increased PD1 expression on CD11c+ B cells in SLE compared to CD11c− (p < 0.0001) and compared to CD11c+ B cells from HD (p < 0.0001) and pSS (p < 0.001) patients (Figure 4B).